Page 15 - Read Online

Cavaller-Bellaubi et al. Rare Dis Orphan Drugs J 2024;3:23 https://dx.doi.org/10.20517/rdodj.2023.58 Page 7 of 8

has played a pivotal role in driving positive change for PLWRD in Europe and beyond.

By 2030, in a new vibrant environment, EURORDIS will have catalysed multi-stakeholder collaborations
and led impactful motivated networks of member organisations as well as new generations of advocates
across diseases and borders. EURORDIS will continue to generate evidence, provide the views and opinions
of PLWRD, and support the integration of the European Action Plan with national actions in key policy
areas.

The organisation’s dedication and collaborative efforts have had a profound impact on the lives of millions,
making it a driving force for the rare disease community. Keeping a steady compass, clear vision, and strong
values will ensure that EURORDIS keeps fulfilling its mission to improve the lives of people with rare
diseases for the years to come.

DECLARATIONS
Acknowledgements
The authors want to thank EURORDIS colleagues, its members and volunteers, for their significant
contributions to the rare diseases’ community during all these years.

Authors’ Contributions
Conception and writing of the manuscript: Cavaller-Bellaubi M, Hivert V, Favresse R, Le Cam Y
Drafting the table and the figure: Cavaller-Bellaubi M, Le Cam Y

Availability of Data and Materials
Not applicable.

Financial Support and Sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical Approval and Consent to Participate
Not applicable.

Consent for Publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. EURORDIS financial report 2022. Available from: https://www.eurordis.org/publications/financial-report-2022/ [Last accessed on 29
Jul 2024].
2. EURORDIS. Available from: https://www.eurordis.org/ [Last accessed on 29 Jul 2024].
3. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products.
2000. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32000R0141&from=EN [Last accessed on
29 Jul 2024].
4. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric
use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text
with EEA relevance). Available from: https://eur-lex. europa.eu/legal-content/EN/TXT/?uri=celex%3A32006R1901 [Last accessed on
29 Jul 2024].